No connection

Search Results

MBAI vs TRIB

MBAI
Check-Cap Ltd.
BEARISH
Price
$1.80
Market Cap
$13.1M
Sector
Healthcare
AI Confidence
95%
TRIB
Trinity Biotech plc
BEARISH
Price
$0.74
Market Cap
$13.9M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
MBAI
--
TRIB
--
Forward P/E
MBAI
--
TRIB
-0.72
P/B Ratio
MBAI
2.8
TRIB
-0.25
P/S Ratio
MBAI
--
TRIB
0.29
EV/EBITDA
MBAI
-2.46
TRIB
-27.89

Profitability

Gross Margin
MBAI
0.0%
TRIB
36.78%
Operating Margin
MBAI
0.0%
TRIB
-3.56%
Profit Margin
MBAI
0.0%
TRIB
-75.88%
ROE
MBAI
-130.12%
TRIB
--
ROA
MBAI
-20.82%
TRIB
-9.46%

Growth

Revenue Growth
MBAI
--
TRIB
-5.5%
Earnings Growth
MBAI
--
TRIB
--

Financial Health

Debt/Equity
MBAI
0.04
TRIB
--
Current Ratio
MBAI
0.71
TRIB
1.03
Quick Ratio
MBAI
0.71
TRIB
0.47

Dividends

Dividend Yield
MBAI
--
TRIB
--
Payout Ratio
MBAI
0.0%
TRIB
0.0%

AI Verdict

MBAI BEARISH

MBAI exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a critical lack of revenue. The company has reported losses for 25 consecutive quarters, with a devastating ROE of -130.12% and a Current Ratio of 0.71, indicating an inability to cover short-term liabilities. While the 1-year price performance shows a speculative rally, the underlying fundamentals are non-existent, and the absence of an Altman Z-Score or Graham Number reflects a lack of stable equity or earnings to support a valuation.

Strengths
Very low Debt/Equity ratio (0.04)
Recent reduction in the magnitude of quarterly losses
Strong 1-year price momentum (+175.7%)
Risks
Severe liquidity risk with a Current Ratio of 0.71
Chronic lack of profitability over 25 consecutive quarters
Zero reported profit and operating margins
TRIB BEARISH

TRIB exhibits significant financial distress, characterized by a Piotroski F-Score of 4/9 (Stable) which masks deeper systemic issues. The most critical red flag is a negative Price-to-Book ratio (-0.25), indicating negative shareholders' equity. Despite a low Price-to-Sales ratio, the company suffers from negative profit margins (-75.88%) and a catastrophic 5-year price decline of 95.8%. Liquidity is precarious with a Quick Ratio of 0.47, suggesting an inability to meet short-term obligations without inventory liquidation.

Strengths
Low Price-to-Sales ratio (0.29) suggests the market is pricing the company well below its revenue
Positive Gross Margin (36.78%) indicates the core product has value before overhead
Recent short-term price recovery (+15.6% over 1 month)
Risks
Negative Shareholders' Equity (P/B of -0.25) indicates insolvency risk
Severe negative profit margins (-75.88%)
Negative year-over-year revenue growth (-5.50%)

Compare Another Pair

MBAI vs TRIB: Head-to-Head Comparison

This page compares Check-Cap Ltd. (MBAI) and Trinity Biotech plc (TRIB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile